No Data
Jiangsu Hengrui Pharmaceuticals sold innovative molecules to Merck in Germany, successfully completing two external licensing deals within half a month.
① Jiangsu Hengrui Pharmaceuticals accelerates its international expansion, achieving two external licensing agreements for Innovative Drugs within half a month; ② In response to tariffs, Jiangsu Hengrui Pharmaceuticals stated that it will continue to closely monitor changes in the international environment and respond flexibly to the complex and changing external conditions, ensuring the company's long-term stability.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Little K broadcasts the morning news | Contemporary Amperex Technology denies that the accident vehicle of Xiaomi is equipped with its Battery. OpenAI releases AI Agent evaluation benchmarks.
① Four departments: Shanghai and nine other cities included in the first batch of pilot zones for large-scale applications of vehicle-network interaction; ② Hubei: Focused support for the cultivation of trillion-level clusters in fields such as Wuhan Asia Vets connected Autos; ③ ShanDong: Plans to issue three action plans integrating culture and Technology, Brain-computer Interface, and quantum Technology.
New executives appointed! Jiangsu Hengrui Pharmaceuticals appoints a new president, aiming to strengthen internationalization?|Quick announcement summary
① Feng Ji, who has worked for AstraZeneca for many years, has officially been appointed as the President and Chief Operating Officer of Jiangsu Hengrui Pharmaceuticals. ② According to industry insiders, the current executive team at Hengrui remains stable, with no significant changes in the roles of other major executives. ③ Industry insiders believe that Jiangsu Hengrui Pharmaceuticals values Feng Ji's experience in multinational pharmaceutical companies.
The entire pharmaceutical sector has surged sharply; what happened?
On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.